Medigene is well funded, with a net cash position of €46.8m (FY15). There is a clear strategy in place to advance both its DC vaccine programmes and TCR programme with the funds. We expect newsflow in the near term from its most advanced technology (DC vaccines) in Phase I/II studies for AML and prostate cancer, and the start of the first clinical study with its promising TCR technology. Our rNPV-based valuation remains at €216m.
06 Apr 2016
An advancing immunotherapies programme
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
An advancing immunotherapies programme
Medigene is well funded, with a net cash position of €46.8m (FY15). There is a clear strategy in place to advance both its DC vaccine programmes and TCR programme with the funds. We expect newsflow in the near term from its most advanced technology (DC vaccines) in Phase I/II studies for AML and prostate cancer, and the start of the first clinical study with its promising TCR technology. Our rNPV-based valuation remains at €216m.